SteelPeak Wealth LLC Cuts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

SteelPeak Wealth LLC lessened its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 15.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,106 shares of the company’s stock after selling 3,000 shares during the period. SteelPeak Wealth LLC’s holdings in Intellia Therapeutics were worth $188,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Eastern Bank acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics during the third quarter worth about $54,000. KBC Group NV increased its holdings in Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock valued at $71,000 after buying an additional 2,340 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Intellia Therapeutics by 182.7% in the 3rd quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock worth $94,000 after acquiring an additional 2,707 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 29,000 shares of company stock worth $352,551. Corporate insiders own 3.20% of the company’s stock.

Analyst Ratings Changes

NTLA has been the subject of several research reports. Barclays reduced their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Robert W. Baird lowered their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company cut their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. BMO Capital Markets lowered their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Finally, Oppenheimer cut their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $10.32 on Friday. Intellia Therapeutics, Inc. has a 1 year low of $9.25 and a 1 year high of $34.87. The firm has a 50 day moving average price of $12.26 and a 200 day moving average price of $17.62. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -1.90 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter in the previous year, the firm posted ($1.38) EPS. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.